It is unimportant at this point. $ELTP's first ADT agonist will be whatever $ELTP and their Litigation IP Lawyers B&H decide is best for $ELTP's business model.
As for the Pain Efficacy trial it is not about the agonist. It is about $ELTP's Naltrexone sequestering polymer to withstand all the body fluids and not leak.
Oxycodone and Morphine analgesic qualities are known by the FDA. What is not known by the FDA is $ELTP Naltrexone sequestering polymer ability to withstand intact against all of the harsh body fluids. That is what the trial results will show.
News 
Market Data 
Discover 
